| Oct 4 |
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
|
| Oct 1 |
3 Undervalued Small Caps In United States With Insider Buying
|
| Sep 7 |
While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership
|
| Aug 30 |
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
|
| Aug 9 |
NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 7 |
NewAmsterdam Pharma GAAP EPS of -$0.41, revenue of $2.27M
|
| Aug 7 |
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
|
| Jul 30 |
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED)
|
| Jul 30 |
NewAmsterdam Pharma (NASDAQ:NAMS) Is In A Good Position To Deliver On Growth Plans
|
| Jul 29 |
NewAmsterdam Pharma announces positive data for its cholesterol reduction drug
|
